Climate change is adversely affecting the burden of infectious disease throughout the world,
which is a health security threat. Climate-sensitive infectious disease includes vector-borne …

Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …

Malaria cases and deaths remain unacceptably high and are resurgent in several settings,
though recent developments inspire optimism. This includes the approval of the world's first …

Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

Background Malaria elimination requires interruption of the highly efficient transmission of
Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that …

Background Seasonal vaccination with the RTS, S/AS01 E vaccine combined with seasonal
malaria chemoprevention (SMC) prevented malaria in young children more effectively than …